

Loss of Complement Factor H impairs antioxidant capacity and energy metabolism of human RPE cells

Angela Armento¹, Sabina Honisch¹, Vasiliki Panagiotakopoulou^{2, 3}, Inga Sonntag¹, Anke Jacob¹, Sylvia Bolz¹, Ellen Kilger¹, Michela Deleidi^{2, 3}, Simon Clark¹; Marius Ueffing^{1*}





¹Institute for Ophthalmic Research, Department for Ophthalmology, Tübingen, Germany.

²German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

³Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany


*corresponding author

Marius.ueffing@uni-tuebingen.de




a**b****c****d**

Suppl. Fig. S1. Expression and localization of RPE markers in experimental conditions. Cells were seeded, let attach overnight and silenced for 24 hours with negative control (siNeg) or *CFH* specific (siCFH) siRNA. Cells were exposed for 90 minutes to 200 μ M H₂O₂ or PBS and after 48 hours RNA was collected. **a.** Gene expression analysis by qRT-PCR of RPE markers: Bestrophin 1 (BEST1), Retinoid


Isomerohydrolase (RPE65), SEM is shown, n=3. Data are normalized to housekeeping gene PRPL0 using $\Delta \Delta C_t$ method. **b.** ZO-1 immunostaining in hTERT-RPE1 cells 24 hours after silencing. **c.** Skeletonized ZO-1 staining based on the images in b. **d.** Histograms showing the quantification of the number and length of ZO-1 fragments, n=6. a.u. arbitrary units. Scale bars: 20 μm .




Suppl. Fig. S2. Levels of sC5b-9 in RPE cells. hTERT-RPE1 cells were seeded, let attach overnight and silenced for 24 hours with negative control (siNeg) or *CFH* specific (siCFH) siRNA. Cell lysates and cell culture supernatants were collected after 48 hours. sC5b-9 ELISA was performed on lysates and cell culture supernatants (SN) and positive controls provided by the manufacturer. SEM is shown, n=3. Lower limit of detection (LOD) 3.7 ng/ml. Lower limit of quantification (LLOQ) 8.8 ng/ml.

a**b****c**

Suppl. Fig. S3. Expression of OxPhos genes, transcription factors and oxidative response genes in experimental conditions. hTERT-RPE1 cells were seeded, let attach overnight and silenced for 24 hours with negative control (siNeg) or *CFH* specific (si*CFH*) siRNA. Cells were exposed for 90 minutes to 200 μ M H₂O₂ or PBS and after 48 hours RNA was collected. **A** Gene expression analysis by qRT-PCR of OxPhos genes: NADH dehydrogenase 4 (ND4), Cytochrome c oxidase subunit 4 (COX4) and mitochondrially encoded ATP synthase 6 (ATP6). SEM is shown, n=3 **B** Gene expression analysis by qRT-PCR of transcription factors: Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha (PGC1a/PPARGC1A) and Nuclear Factor, Erythroid 2 Like 2 (NRF2/NFE2L2). SEM is shown, n=3 **C** gene expression analysis by qRT-PCR of genes involved in oxidative stress response: peroxiredoxin 3 (PRDX3), catalase (CAT), Glutathione Peroxidase 1 (GPX1). SEM is shown, n=3. Data are normalized to housekeeping gene PRPL0 using $\Delta \Delta$ Ct method. Significance was assessed by Student t-test (single effect) and two-way ANOVA (combined effects) as described in the methods section. * p<0.05, ** p<0.01.



Suppl. Fig. S4. Assessment of optimal concentration for H₂O₂ pre-treatment. hTERT-RPE1 cells were seeded, let attach overnight and exposed for 90 minutes to increasing concentrations of H₂O₂ and after 48 hours cell density was analyzed via Crystal Violet staining.



Suppl. Fig. S5. Original full images of Western Blots acquired with FusionFX instrument (Vilber Lourmat, France) and software provided by the manufacturer using automatic modus. **a.** corresponds to Fig. 1b. **b** corresponds to Fig. 1d. Boxes highlight the cropped bands reported in Fig. 1. Additional bands represent the cleaved forms of the protein of interest.

The EYE-RISK Consortium

Soufiane Ajana¹, Blanca Arango-Gonzalez², Angela Armento², Franz Badura⁴, Ulrich Bartz-Schmidt², Berta De la Cerda⁵, Marc Biarnés⁶, Anna Borrell⁶, Johanna M. Colijn^{8,9}, Audrey Cougnard-Grégoire¹, , Eiko K. de Jong¹⁰, Cécile Delcourt¹, Anneke I. den Hollander^{10,11}, Sigrid Diether², Eszter Emri¹², Tanja Endermann³, Lucia L. Ferraro⁶, Míriam García⁶, Thomas J. Heesterbeek¹⁰, Sabina Honisch², A Ikram⁸, Eveline Kersten¹⁰, Ellen Kilger², Caroline C.W. Klaver^{8,9,10}, Eloed Kortvely^{2,13}, Hanno Langen¹³, Claire Lastrucci¹⁸, Imre Lengyel¹², Phil Luthert¹⁴, Magda Meester-Smoor^{8,9}, Bénédicte M.J. Merle¹, Jordi Monés⁶, Everson Nogoceke¹³, Tunde Peto¹⁵, Frances M. Pool¹⁶, Eduardo Rodríguez⁶, Luis Serrano¹⁸, Marius Ueffing², Timo Verzijden^{8,9}, Johannes Vingerling⁹, Markus Zumbansen¹⁷.

¹ Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team LEHA, UMR 1219, Bordeaux, France. ² Department of Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University Tuebingen, University Clinic Tuebingen, Tuebingen, Germany. ³ Assay Development, AYOXXA Biosystems GmbH, Cologne, Germany. ⁴ Pro-Retina Deutschland, Aachen, Germany. ⁵ Department of Regeneration and Cell Therapy, Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Seville, Spain. ⁶ Barcelona Macula Foundation, Barcelona, Spain. ⁷ Business Development, AYOXXA Biosystems GmbH, Cologne, Germany. ⁸ Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. ⁹ Department of Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands. ¹⁰ Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands. ¹¹ Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. ¹² Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom. ¹³ Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland. ¹⁴ Institute of Ophthalmology, University College London, London, United Kingdom. ¹⁵ Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom. ¹⁶ Ocular biology, UCL Institute of Ophthalmology, London, United Kingdom. ¹⁷ Research and & Development, AYOXXA Biosystems GmbH, Cologne, Germany. ¹⁸ Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain.